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Introduction: The number of elderly patients with advanced chronic kidney disease (ACKD)
has increased in recent years, and the best therapeutic approach has not been determined
due  to a lack of evidence.
Objectives: To observe the progression of elderly patients with ACKD (stages 4 and 5) and to
compare the survival of stage 5 CKD patients with and without dialysis treatment.
Material and methods: All patients ≥70 years who began ACKD follow-up from 01/01/2007
to  31/12/2008 were included, and their progression was observed until 31/12/2013. Demo-
graphic data, the Charlson comorbidity index, history of ischaemic heart disease (IHD) and
diabetes mellitus (DM) were assessed.
Results: A total of 314 patients ≥70 years with stages 4 and 5 CKD were studied. Of these
patients, 162 patients had stage 5 CKD at the beginning of follow-up or progressed to stage
5  during the study, and 69 of these patients were treated with dialysis. In the stage 5 group,
median age was 77 years (74–81); 48% had IHD; 50% had DM, Charlson 7 (6–9). Kaplan–Meier
survival analysis: ≥70 years (93 vs. 69 patients with dialysis, log rank: 15 p < 0.001); patients
≥75  years (74 vs. 46 patients with dialysis, log rank: 8.9 p = 0.003); patients ≥80 (40 vs. 15
patients with dialysis) and p = 0.2. Patients receiving dialysis were younger, with a lower
Charlson comorbidity index and shorter follow-up time.
Conclusions: Our study shows that dialysis treatment improves survival, although this ben-
eﬁt  is lost in patients ≥80 years.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Supervivencia  de  pacientes  de  edad  avanzada  (≥70  an˜os)  con  enfermedad
crónica  estadios  4-5:  diálisis  vs  tratamiento  conservador
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Introducción: Los pacientes de edad avanzada que llegan a enfermedad renal crónica avan-
zada (ERCA) se han incrementado en los últimos an˜os. No hay evidencia de la mejor actitud
terapéutica en estos pacientes.
Objetivos: Observar la evolución de pacientes ancianos en consulta de ERCA (estadios 4 y 5)
y  comparar la supervivencia de los pacientes con ERC estadio 5 tratados con diálisis o no.
Material y métodos: Se incluyó a todos los pacientes con ≥70 an˜os que iniciaron seguimiento
en  consulta de ERCA desde el 1-1-2007 hasta el 31-12-2008 y se observó su evolución
hasta  el 31-12-2013. Se recogieron datos demográﬁcos, índice de comorbilidad de Charlson,
antecedentes de cardiopatía isquémica (CI) y diabetes mellitus (DM).
Resultados: Se estudió a 314 pacientes con ERC estadios 4 y 5 con ≥70 an˜os, 162 de los cuales
estaban en el momento del inicio del seguimiento o a lo largo del mismo en estadio 5; 69 de
estos  pacientes recibieron tratamiento con diálisis. En el grupo estadio 5: mediana de edad
de  77 an˜os (74-81); 48% CI; 50% DM; Charlson 7 (6-9). Supervivencia Kaplan-Meier: ≥70 an˜os
(93  vs. 69 pacientes con diálisis) log rank: 15 (p < 0,001), con ≥75 an˜os (74 vs. 46 pacientes con
diálisis; log rank: 8,9; p = 0,003), con ≥80 an˜os (40 vs. 15 pacientes con diálisis) y p=0,2. Los
pacientes que recibieron tratamiento con diálisis tenían menor edad e índice de Charlson
y  el tiempo de seguimiento en consulta era inferior.
Conclusiones: En nuestro estudio el tratamiento con diálisis mejora la supervivencia, si bien
esta  ventaja se pierde en los pacientes con ≥80 an˜os.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
The number of elderly patients with advanced chronic kid-
ney disease (ACKD), estimated glomerular ﬁltration rate (eGFR)
under 30 ml/min/1.73 m2, stages 4 and 5 according to the DOQI
classiﬁcations,1 has increased dramatically.2 In some series,
it has doubled during the last 25 years.3 In our area, accord-
ing to the 2013 data from the Kidney Transplant Coordination
Data System of Andalusia (SICATA), a database of kidney
patients treated with dialysis and transplantation in Andalu-
sia, patients over 70 accounted for 38% of the incident patients
and 41.4% of the prevalent patients in dialysis programmes.4
Among the ACKD consultations in our hospital in 2013, adults
70 or older accounted for 58% of incident patients and up to
66% of the prevalent patients. Longer life expectancies and
medical advances have contributed to the increased period
of time for the development of renal atherosclerosis and dia-
betes mellitus (DM). During the past years, these patients died
before reaching an advanced stage of CKD.5 It is currently
unclear whether in this group of patients renal replacement
therapy (RRT) is the best option as compared with conser-
vative treatment, since a large proportion of them present
an increased fragility, with high indices of dependence and
higher comorbidity, including DM,  atherosclerosis in several
locations, heart disease, with or without heart failure, difﬁ-
cult vascular access, etc. Therefore RRT may not improve their
survival11–13 much less their quality of life. In this regard, it
should be taken into account how a speciﬁc patient is affected
by the change in lifestyle from the dialysis technique itself
(exchanges in peritoneal dialysis, travel to dialysis centres,by-nc-nd/4.0/).
following schedules, dependence on other caretakers or family
members, etc.) and its complications (decreased function after
sessions, high rate of hospitalisations, use of venous catheters
and their complications, etc.).14,15
Currently, there is a growing interest in evaluating the pos-
sibility of a more  conservative treatment for elderly ACKD
patients.7 It must be speciﬁed that conservative treatment in
this patient group should not entail an “absence of treatment”
or less specialised medical care.8–10 Conservative treatment
implies patient care in ACKD clinics with multidisciplinary
approach to provide the best quality of life possible to end-
stage kidney disease patients not eligible for dialysis therapy.
Our objectives in this study were to discover the long-term
progression of elderly incident ACKD (stages 4 and 5) patients
in our out patient clinics and to retrospectively compare sur-
vival in the group of CKD stage 5 patients who underwent
dialysis with those who followed a conservative treatment.
Methods
Retrospective, observational study including all patients 70 or
older who began follow-up in the ACKD clinic of the Nephrol-
ogy Department of the Hospital Universitario Virgen del Rocío
in Seville (hospital area includes 1,400,000 habitants) from Jan-
uary 1, 2007 through December 31, 2008 and whose progress
was observed for a 5-year period; the end of observational
period was December 31, 2013. The database from our own
ofﬁce was used to identify patients and collect follow-up infor-
mation. The DAE system (electronic data platform) used by
the public health system of Andalusia was also employed to
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egistry.
Kidney function at the ﬁrst visit to the ACKD clinic was
omputed as baseline estimated GFR using the MDRD-4 equa-
ion. Renal function was also computed when patients entered
tage 5 (eGFR < 15 ml/min/1.73 m2), in the case that the patient
eached this stage during the follow-up period. The following
ata were extracted from their medical records: cause of kid-
ey disease, vascular access in the case of patients who started
aemodialysis, history of DM,  ischaemic heart disease (under-
tood as an ischaemic episode), Charlson comorbidity index
alculation, follow-up period in the clinic before they left, and
heir reason for leaving (death, dialysis, or end of the observa-
ion period on December 31, 2013). For patients who died, the
ate and cause were recorded when it occurred in our hospi-
al or at home after a previously known disease process. We
ere not able to determine the cause of death if patient died
n another hospital.
A descriptive analysis was conducted on the different
uantitative variables using the median and the 25th and
5th percentiles, since they did not show a normal distribu-
ion; qualitative variables were expressed as the number and
ercentages. The Mann–Whitney U test and chi-squared test
ere used to analyse the difference between patients with
15 ml/min/1.73 m2 who received dialysis and those who did
ot, and between the patients who died and those alive at
he end of the follow-up. The analysis was performed in both
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Fig. 1 – Flow chart and progression of patie(3):283–291 285
the entire group (314 patients) and in stage 5 patients (162
patients). The Kaplan–Meier and log-rank methods were used
to estimate and compare survival in both groups. The Cox
proportional hazards regression was used to investigate the
impact of dialysis and other independent variables on sur-
vival. First, the correlation between each variable (age, eGFR,
history of DM, history of ischaemic heart disease, Charlson
index, and dialysis treatment) and survival (dependent vari-
able) was independently analysed in a bivariate regression
analysis. Then, the variables that were signiﬁcant and those
considered to have speciﬁc clinical signiﬁcance were included
in the Cox regression analysis. The IBM SPSS-19 statistical
package was used.
Results
Initially 348 patients were studied who were 70 or older seen
for the ﬁrst time in the ACKD ofﬁce successively during the
speciﬁed follow-up period. During the follow-up, 16 patients
recovered kidney function and went/returned to the General
Nephrology clinic. Similarly, 18 patients were lost to follow-
up. These 348 patients accounted for 61% of all 571 patients of
all ages seen for the ﬁrst time during the inclusion period.
The ﬁnal sample was made up of 314 patients; of these,
242 began their follow-up in stage 4 CKD and 90 (37%) pro-
gressed to stage 5. At the time of their ﬁrst visit (in the
 1/1/2007 to 31/12/2008)
. 
72 patients
Stage 5 CKD
162 patients
Stage 5 CKD
subgroup
52 patients
Living
2 patients
ffice follow-up 
 30 patients
Dialysis
110 patients
Died
ears 18 patients: Lost to follow-up
16 patients: Recovered kidney function to
stage 3
nts from their inclusion in the study.
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Table 1 – Demographic data.
Full group
(n = 314)
CKD 5 subgroup
(n = 162)
Age in years, n (range) 77 (74–81) 77 (74–81)
Male, n (%) 143 (46) 89 (55)
Diabetes mellitus, n (%) 157 (50) 81 (50)
Charlson index, n (range) 8 (7–9) 7 (6–9)
Ischaemic heart disease, n (%) 159 (51) 78 (48)
Baseline eGFR
(ml/min/1.73 m2), n (range)
20 (16–26) 14 (12–14)
In-ofﬁce follow-up (months), n
(range)
41 (13–64) 15 (6–35)
Deaths, n (%) 196 (64) 110 (68)
Survival (months), median
(25–75th percentile)
56  (25–67) 53 (29–67)
case of 72 patients) or during the follow-up (in the case of
the 90 patients mentioned above) 162 patients reached stage
5 (eGFR < 15 ml/min/1.73 m2). Fig. 1 displays this information
schematically.
None of the patients was discarded, despite the fact that in
some cases their eGFR was greater than 30 ml/min/1.73 m2 as
there was a slight transitory improvement. In the case where
this improvement lasted, they were sent back to the General
Nephrology clinic. The demographic data and other character-
istics for both the full group (314 patients) and the subgroup of
patients with stage 5 CKD (162) are shown in Table 1. Table 2
shows the survival in the 2 groups by year of follow-up and
the overall survival from the ﬁrst visit (baseline) until the end
of the follow-up period or death. As for the 90 patients who
started with an eGFR in stage 4 and progressed to stage 5,
survival was considered since the time the eGFR was under
15 cc/m/1.73 m2.
In the group of 69 patients who underwent dialysis (87%
haemodialysis, 13% peritoneal dialysis), 35 patients (51%) had
a vascular access, 18 patients (26%, in 10 cases vascular access
was requested) started with a transitory venous catheter, type
of access was unknown in 7 patients (10%), and 9 patients had
a peritoneal catheter (13%). The median time in dialysis was
27 months (9–51) for the entire group of ≥70 y.o., 30 months
(14–46) for the 46 patients ≥75 y.o., and 14 months (2–39) for
the 15 patients ≥80 y.o. For the subgroup of 54 patients 70–80
Table 2 – Survival by year of follow-up and total.
Full group
(n = 314)
CKD  5
subgroup
(n = 162)
1 year 261 121
2 years 235 97
3 years 231 75
4 years 169 52
5 years 131 33
Survival since baseline,
months, median
(25–75th percentile)
56  (25–67) 53 (29–67)
Survival since stage 5,
months, median
(25–75th percentile)
33  (12–57);3 6(3):283–291
y.o., the median time in dialysis was 30 months (10–52). None
of the patients received a transplant.
Comparison  of  deaths  vs.  surviving  patients  (full  group
and stage  5  subgroup)
The difference between patients who died and alive was ana-
lysed; Table 3 displays the results in both the full group and in
the subgroup with stage 5 CKD. The most frequent causes of
death in the full group (196 deaths) were: cardiovascular dis-
ease in 137 patients (70%) and cancer in 24 patients (12%). Data
regarding the cause of death was not available in 15 patients
(8%).
Comparison  of  dialysis  vs.  conservative  treatment
(subgroup  of  162  stage  5  patients)
Table 4 shows the demographic data for the group comparing
those who received dialysis and those who did not.
The Kaplan–Meier analysis conﬁrmed that the survival was
better in patients that were dialyzed: 69 vs. 93 patients in con-
servative treatment aged 70 or older (log-rank: 15.4; p < 0.001).
An additional sub-analysis was performed in 120 patients
aged 75 or older (median 77; 25–75th percentile: 74–81 years)
(46 vs. 74 patients without dialysis), survival being higher in
patients receiving dialysis (log-rank: 8.9; p = 0.003). Similarly,
the group of 55 patients aged 80 or over was analysed (median
82; 25–75th percentile: 81–84 years, 15 vs. 40 without dialysis);
in this group patients receiving dialysis did not show statistical
increase in survival as compared with conservative treatment
(log-rank: 1.6; p = 0.2). Fig. 2 shows the survival curves for the
3 patient groups by age.
Cox  regression  (subgroup  of  162  stage  5  patients)
To determine which variables inﬂuence survival in this group
over time, a Cox regression analysis was completed, using sur-
vival time as the dependent variable. Among the variables
initially assessed independently using bivariate regression, we
found the following results: follow-up time in the ofﬁce (HR:
0.95; p < 0.001), baseline eGFR (MDRD-4) (HR: 0.96; p = 0.001),
age (HR: 1.04; p = 0.008), dialysis (HR: 1.68; p = 0.01). There was
no statistically signiﬁcant correlation with sex, comorbidity as
measured by the Charlson index, history of diabetes, or history
of ischaemic heart disease.
The statistically signiﬁcant variables in the bivariate
regression with survival and the non-signiﬁcant variables that
have clinical relevance (ischaemic heart disease and DM)  were
included to determine the effect that each one has in the
Cox regression model: age, kidney function as measured by
the MDRD-4 eGFR, dialysis, and time in the ofﬁce. History of
ischaemic heart disease, history of DM, and age were not sta-
tistically signiﬁcant in the multivariate analysis. The resulting
hazard ratios indicate that, in our study, dialysis, follow-up
time in the ofﬁce, and baseline kidney function were the
most important variables for survival in our group of patients
(Table 5).
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Table 3 – Death vs. no death.
Full group Grade 5 CKD subgroup
No death n = 118 Death n = 196 p No death n = 52 Death n = 110 p
Age in years, median (25–75th
percentile)
77  (73–79) 77 (74–82) 0.01 77 (73–80) 77 (75–81) 0.1
Sex (M), n (%) 69 (58) 102 (52) 0.1 29 (56) 60 (55) 0.5
Diabetes mellitus, n (%) 51 (43) 106 (54) 0.04 22 (42) 59 (54) 0.1
Charlson index, median (25–75th
percentile)
8  (7–9) 8 (7–9) 0.9 7 (6–9) 8 (6–9) 0.2
Ischaemic heart disease, n (%) 52 (44) 107 (55) 0.03 23 (44) 55 (50) 0.3
eGFR (ml/min/1.73 m2), median
(25–75th percentile)
21.2  (16.8–26.5) 19.7 (14.1–5.8) 0.05 16.6 (14.3–20.8) 15.1 (12.5–21.5) 0.1
Stage 5 eGFR (ml/min/1.73 m2),
median (25–75th percentile)
13  (12.2–14.5) 13.5 (12–14.3) 0.3
In-ofﬁce follow-up (months),
median (25–75th percentile)
66  (60–74) 25 (7–46) <0.001 61 (35–70) 25 (7–46) <0.001
In-ofﬁce follow-up since stage 5
(months), median (25–75th
percentile)
30  (11–63) 11 (3–24) <0.001
Survival since baseline (months),
median (25–75th percentile)
69  (64–77) 36 (12–50) <0.001 70 (65–77) 39 (15–56) <0.001
Survival since stage 5 (months),
median (25–75th percentile)
58  (39–71) 21 (8–41) <0.001
Dialysis, n (%) 30 (25) 39 (20) 0.1 30 (58) 39 (35) 0.006
Table 4 – Dialysis vs. no dialysis stage 5 CKD subgroup (n = 162).
Dialysis n = 69 No dialysis n = 93 p
Age, median (25–75th percentile) 76 (73–79) 78 (75–82) 0.004
Sex (M) 35 (51%) 54 (58%) 0.2
Diabetes mellitus 34 (49%) 47 (51%) 0.5
Charlson index, median (25–75th percentile) 7 (6–8) 8 (7–9) <0.001
Ischaemic heart disease 36 (52%) 42 (45%) 0.2
In-ofﬁce follow-up, months, median (25–75th percentile) 10 (5–21) 22 (5–42) 0.008
Survival, months 65 (52–70) 39 (14–60) <0.001
I
5
A
tSurvival since stage 5, months, median (25–75th percentile) 
Stage 5 eGFR (ml/min/1.73 m2), median (25–75th percentile) 
nﬂuence  of  comorbidity  on  survival  (full  group  and  stage
 subgroup)n additional survival analysis was performed (Fig. 3) among
he group of stage 5 patients with ischaemic heart disease
1.0 P:<.001
Patients ≥ 75 year Patients ≥  70 years (n=162)
Dialysis
No dialysis No dialysis
0.8
0.6
0.4
0.2
0.0
0 12
No dialysis
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1420304357 6
1832455464 7
No dialysis
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233245
293443
7260483624
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0.6
0.4
0.2
0.0
0 362412
Fig. 2 – Effect of dialysis treatment on survival by age gr46 (27–62) 21 (7–42) <0.001
14 (11–14) 14 (12–14) 0.7
(n = 78) to determine whether dialysis still had a favourable
effect on survival in this subgroup of patients. The results
showed that dialysis did favour survival (36 dialysis vs. 42
without dialysis; log-rank 14.7; p < 0.001). Similarly, the effect
of dialysis in the group of patients with DM  (n = 81) was
.2P:.003P:
s (n=120) Patients ≥ 80 years (n=55)
DialysisDialysis
No dialysis
1115 2
19 8 3
No dialysis
Dialysis
131623 8 7 2
13 9 6 4 2 1
726048
1.0
0.8
0.6
0.4
0.2
0.0
0 726048362412
oup (stage 5 CKD patients): dialysis vs. no dialysis.
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DialysisDialysis
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Fig. 3 – Patient subgroups with ischaemic heart disease, diabetes mellitus, or high Charlson comorbidity index. Effect of
dialysis treatment on survival.
Table 5 – Cox regression: variables inﬂuencing survival
over time.
HR (95% CI) p
Age 0.99 (0.95–1.04) 0.8
Diabetes mellitus 1.06 (0.69–1.6) 0.7
Charlson index 0.89 (0.79–1.03) 0.1
Ischaemic heart disease 0.88 (0.59–1.32) 0.5
Baseline eGFR 1.10 (1.06–1.14) <0.001
Time in ofﬁce 0.93 (0.92–0.95) <0.001
Treatment with dialysis 0.05 (0.03–0.10) <0.001
treated with dialysis than in a conservative treatment; how-
ever this advantage is lost in patients ≥80 years. In addition toanalysed, demonstrating that patients treated with dialysis
had a better survival (34 vs. 47 patients without dialysis; log-
rank 26; p < 0.001). Among the patients (n = 80) with a high
Charlson index (over 7, the group median), the difference
in survival with dialysis was also signiﬁcant (log-rank 6.9;
p = 0.008).
1.0
.1P:
Ischaemic heart dDiabetes mellitus (n=162)
DM
No DM
0.8
0.6
0.4
0.2
0.0
0 12
No DM
DM
1829425265 9
1523334556 5
No IHD
IHD
45266
34555
7260483624
1.0
0.8
0.6
0.4
0.2
0.0
0 32412
Fig. 4 – Inﬂuence of history of ischaemic heart disease, diabetes 
kidney disease subgroup (162 patients).The effect of a history of DM or ischaemic heart disease
and a high Charlson index in stage 5 CKD patients was also
analysed and no signiﬁcant differences were found (Fig. 4).
In the entire group (314 patients) this analysis showed that
ischaemic heart disease did affect survival (as seen with the
Chi-squared test, Table 2) log-rank 4.2; p = 0.04. As for DM,
the difference is close to statistical signiﬁcance (log-rank 3.3;
p = 0.06), and there were no differences in survival for a Charl-
son index over 8 (group median) (Fig. 5).
Discussion
The results from our study in patients with advance age (≥70
years) with stage 5 CKD show that survival was higher in thosedialysis, survival in stage 5 patients was improved inpatients
with a long time of follow up in the outpatient clinic and was
.1P:.6P:
isease (n=162) Charlson 7 (n=162)
IHD Charlson ≤ 7
No IHD
Charlson > 7
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Charlson ≤ 7
1522324256 8
1830435565 5
7260486
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0.4
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0.0
0 726048362412
mellitus, and Charlson index on survival. Stage 5 chronic
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1.0
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DM IHD Charlson ≤ 8
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Fig. 5 – Inﬂuence of history of ischaemic heart disease, diabetes mellitus, and Charlson index on survival. Full group (314
patients).
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bot changed in relation to a higher comorbidity as measured
y the Charlson index and a history of DM or ischaemic heart
isease. Considering all patients (314 patients, stages 4 and
), survival was lower in patients with a history of DM and
schaemic heart disease.
For ethical and technical reasons randomised studies are
ot possible in this ﬁeld; several studies, all observational,
ostly conducted in the United Kingdom, have observed the
linical outcome of elderly patients included in dialysis pro-
rammes, and a few reports have compared clinical outcome
n elderly on dialysis vs. conservative treatment. In general,
t was shown that patients have better survival on dialysis,
lthough this advantage is lost in patients with medical his-
ory of ischaemic heart disease.11 Comorbidity as measured by
he Charlson index16 or in patients with several mortality risk
actors considered six months after starting dialysis.17 Simi-
arly, longer survival may not be signiﬁcant if hospitalisation
ays or those dedicated to dialysis sessions are subtracted,
s shown in the work by Da Silva-Gane.16 The 404-day differ-
nce in survival in patients treated with dialysis is to some
xtent lost if the 326 days allocated to haemodialysis sessions
re subtracted. The case of peritoneal dialysis has different
nterpretation, since patients do not need to travel.
The results from this study are very similar to those pre-
iously published. In the study by Hussain,18 with a group
f patients very similar to ours in which survival in patients
ver 70 years with eGFR of 15 ml/min/1.73 m2 was compared
o patients treated conservatively vs. those treated with dial-
sis, overall survival was improved, although, like in our
tudy, it was lost in those patients older than 80 years and in
atients with higher comorbidity, as measured by the Charl-
on index, among others. The study by Murtagh,11 like ours,
lso observed that survival was longer in patients treated with
ialysis, especially in patients referred early to ACKD outpa-
ient clinics with a higher eGFR. It is unclear if this advantage
n survival comes from the dialysis itself or from correctly
creening and care of patients in those visits. However, this
eneﬁt was substantially lost in those cases that presentedhigher comorbidity indices, particularly with the presence of
ischaemic heart disease. Conversely, in our study we  did not
ﬁnd any differences relating to comorbidity in the stage 5
CKD group (we  did observe a difference in our full group of
314 patients in stages 4 and 5), and in patients with DM and
ischaemic heart disease the positive effect of dialysis on sur-
vival was still present. One explanation may be the lower
number of patients, which lowers the statistical power; also
many patients have both DM and ischaemic heart disease. So
the sample of patients is homogeneous. There was also no dif-
ference in the prevalence of DM and ischaemic heart disease
among those who received dialysis and those who  did not,
but there was a difference in being younger and in the Charl-
son index of the patients treated with dialysis, which implies
that the patients were screened and those who  were younger
and had a lower comorbidity were included in dialysis which
favoured survival in addition to the treatment. This is in line
with previous studies which warned about the importance of
personalising the treatment (dialysis vs. conservative) in each
elderly patients based on their comorbidity.6–10,14–16
In our study patients (the full group with stages 4 and 5
CKD as well as in the stage 5 CKD group) that visited our out-
patient clinics for long period of time have better survival in
both the individual analysis as well as after adjusting for the
different variables in the multivariate analysis. Our results are
similar to other previously published results, such as the paper
by De Nicola,19 in which patients seen for ACKD were followed
for one year. They concluded that patients seen for a longer
time had a lower risk of mortality. Previous follow-up in ACKD
ofﬁces is an important factor in preparing these patients to
choose the dialysis modality according to each patient’s situ-
ation which may condition the short- and mid-term prognosis
in RRT.20–22 A short period of visits to the ofﬁce correlated with
serious non-CKD-related comorbid processes that caused the
early death, unrelated to follow-up in the ofﬁce.
Another noteworthy point is the slow deterioration in kid-
ney function in our patients despite signiﬁcant deterioration
at baseline, with a median eGFR near 20 ml/min/1.73 m2 (after
 0 1 6
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18. Hussain JA, Mooney A, Russon L. Comparison of survival
analysis and palliative care involvement in patients aged over
70  years choosing conservative management or renal290  n e f r o l o g i a. 2
5 years of follow-up: 27% did not reach stage 5; 35% died
before progressing to stage 5; 37% progressed to stage 5). This
evolution has been previously described and it may be justi-
ﬁed in part or in many  cases by the absence of albuminuria,
more  common in patients with concomitant low ﬁltration rate
and albuminuria.23,24 In any case, current knowledge does not
enable us to identify patients with ACKD who will progress
and those who  will not. In our study, the possibility of dying
was similar to that of progressing to stage 5 in patients who
started follow-up in stage 4. In other studies, the risk of dying
was higher than progressing to end-stage CKD.25,26 It is pos-
sible that, had we  considered a lower eGFR in our study,
such as 8–10 ml/min/1.73 m2 instead of 15 ml/min/1.73 m2,
the probability of dying would have been clearly higher
than that of progressing and considering treatment with
dialysis.
The limitations of the present study include the unavail-
ability of additional data that could potentially condition
mortality or survival, such as family support, autonomy, qual-
ity of life data after starting RRT or conservative treatment.
The scarce number of patients in the older subgroups treated
with dialysis must also be pointed out. This study was per-
formed in a single centre, and ﬁndings might not apply fully
to other patient groups. Missing from our study is informa-
tion on patients who did not receive dialysis, whether they
had abandoned the treatment, refused it, or had a medi-
cal contraindication. The results, which show higher ages
and Charlson index in patients who received dialysis, make
this last option more  likely, since the patients were clearly
screened.
The study was conducted in a single centre, so it has the
advantage of being a homogeneous population of patients
and that the treatment applied was uniform in all patients
according to our current CKD patient handling guidelines. The
inclusion period was short, and this favoured a similar treat-
ment for all patients with similar criteria and same drugs
available. It is also important that the follow-up time was long,
more  than 5 years.
Patients of other studies were compared based on the
intention to treat or the initial decision on either RRT or
conservative treatment. Our study compares outcomes of
treatment followed by the patient, which reﬂects reality and
increases its usefulness of our data that can be used as a tool
for counselling patients. Patients ask about speciﬁc outcomes,
so they can decide on modality of treatment: Dialysis or con-
servative treatment. Treatment with dialysis in many  cases
involves a worsening of quality of life, and according to our
study in some cases did not even extend survival as compared
with those who followed a conservative treatment; therefore
treatment must always be personalised. Innovative strategies
such as home care for elderly ACKD patients who accept or
choose conservative treatment for kidney failure in its most
advanced phase may improve the quality of life of the patients
and their family, as it has been doing in some hospitals in our
country.27
In conclusion, in our group of elderly patients (≥70 years),
we have observed that dialysis treatment improves survival in
screened patients, with lower ages and comorbidity indices.
This result was favoured by extended follow-up periods in the
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